JP2013532664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532664A5 JP2013532664A5 JP2013520904A JP2013520904A JP2013532664A5 JP 2013532664 A5 JP2013532664 A5 JP 2013532664A5 JP 2013520904 A JP2013520904 A JP 2013520904A JP 2013520904 A JP2013520904 A JP 2013520904A JP 2013532664 A5 JP2013532664 A5 JP 2013532664A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- group
- substituent
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000015636 Oligopeptides Human genes 0.000 claims 4
- 108010038807 Oligopeptides Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003827 glycol group Chemical group 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000000837 carbohydrate group Chemical group 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002960 lipid emulsion Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002159 nanocrystal Substances 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- HQYKCINCOCLADC-MAUPUACNSA-N CN(/C(/C=C1)=C(\C(C=C2)=N/C2=C(\c2ccc(/C(/c3cccc(O)c3)=C3\N=C4CCC3)[nH]2)/c2cccc(O)c2)/c2cccc(O)c2)/C1=C4/c1cccc(O)c1 Chemical compound CN(/C(/C=C1)=C(\C(C=C2)=N/C2=C(\c2ccc(/C(/c3cccc(O)c3)=C3\N=C4CCC3)[nH]2)/c2cccc(O)c2)/c2cccc(O)c2)/C1=C4/c1cccc(O)c1 HQYKCINCOCLADC-MAUPUACNSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36670710P | 2010-07-22 | 2010-07-22 | |
| PCT/US2011/047576 WO2012012809A2 (en) | 2010-07-22 | 2011-08-12 | APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532664A JP2013532664A (ja) | 2013-08-19 |
| JP2013532664A5 true JP2013532664A5 (enExample) | 2014-10-02 |
Family
ID=45497505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520904A Pending JP2013532664A (ja) | 2010-07-22 | 2011-08-12 | ＰＤＴのためのβ−官能化ジヒドロキシ−クロリンの用途 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2870159B1 (enExample) |
| JP (1) | JP2013532664A (enExample) |
| CN (1) | CN103097390B (enExample) |
| BR (1) | BR112013001576A2 (enExample) |
| IL (1) | IL224381B (enExample) |
| MX (1) | MX353394B (enExample) |
| PL (1) | PL2870159T3 (enExample) |
| WO (1) | WO2012012809A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103096887B (zh) * | 2010-07-22 | 2017-12-29 | 拜欧利泰克投资二代公司 | 用于抗微生物光动力疗法的糖取代的二羟基‑二氢卟酚和β‑官能化二氢卟酚 |
| WO2013015774A1 (en) | 2011-07-22 | 2013-01-31 | Biolitec Pharma Marketing Ltd | Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy |
| CN103995045A (zh) * | 2014-05-29 | 2014-08-20 | 武汉矽感科技有限公司 | 离子迁移谱仪用于检测乐果和马拉硫磷残留的用途及方法 |
| EP3292129B1 (en) * | 2015-05-07 | 2019-03-27 | Luzitin S.A. | Low molecular weight halogenated porphyrine carboxamide chlorin and bacteriochlorin derivatives for use in photodynamic therapy for treating cancer |
| US9722103B2 (en) | 2015-06-26 | 2017-08-01 | Sunpower Corporation | Thermal compression bonding approaches for foil-based metallization of solar cells |
| CN104940950B (zh) * | 2015-07-09 | 2017-11-28 | 武汉大学 | 一种肿瘤靶向多肽光敏剂键合物 |
| CN111196819B (zh) * | 2018-11-16 | 2023-03-28 | 中国科学院上海药物研究所 | 一类d-a-d型苯并吡嗪类化合物及制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648485A (en) * | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| FR2877943B1 (fr) * | 2004-11-16 | 2008-09-05 | Univ De Coimbra | Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique |
| US9315510B2 (en) * | 2008-09-18 | 2016-04-19 | Biolitec Pharma Marketing Ltd | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT |
| JP6041360B2 (ja) * | 2011-07-22 | 2016-12-07 | バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト | 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン |
-
2011
- 2011-08-12 BR BR112013001576A patent/BR112013001576A2/pt not_active Application Discontinuation
- 2011-08-12 PL PL11810524T patent/PL2870159T3/pl unknown
- 2011-08-12 CN CN201180039522.7A patent/CN103097390B/zh active Active
- 2011-08-12 MX MX2013000877A patent/MX353394B/es active IP Right Grant
- 2011-08-12 JP JP2013520904A patent/JP2013532664A/ja active Pending
- 2011-08-12 EP EP11810524.6A patent/EP2870159B1/en active Active
- 2011-08-12 WO PCT/US2011/047576 patent/WO2012012809A2/en not_active Ceased
-
2013
- 2013-01-23 IL IL224381A patent/IL224381B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Nanoparticle‐mediated delivery of inhaled immunotherapeutics for treating lung metastasis | |
| JP2013532664A5 (enExample) | ||
| US12296017B2 (en) | Bioorthogonal compositions | |
| Han et al. | Dual roles of graphene oxide to attenuate inflammation and elicit timely polarization of macrophage phenotypes for cardiac repair | |
| JP7022066B2 (ja) | 代謝機能不全によって引き起こされる腫瘍の治療 | |
| US10011635B2 (en) | Cyclic peptide conjugates and methods of use | |
| Roh et al. | Inhalable mRNA vaccines for respiratory diseases: a roadmap | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| CA2983312A1 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
| JP2018538306A5 (enExample) | ||
| JP2014515407A5 (enExample) | ||
| JP2019513868A5 (enExample) | ||
| TWI869568B (zh) | 新穎之氫醌衍生物 | |
| Holt et al. | Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells | |
| Deng et al. | Probiotic Delivery for Editing of the Gut Microbiota to Mitigate Colitis and Maintain Hepatic Homeostasis Via Gut–Liver Axis | |
| Chang et al. | Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl4-induced hepatic fibrosis in mice | |
| JP2012525391A5 (enExample) | ||
| Li et al. | The Recombinant and Reconstituted Novel Albumin–Lidamycin Conjugate Shows Lasting Tumor Imaging and Intensively Enhanced Therapeutic Efficacy | |
| Wang et al. | Discovery of Airway-Administered Ionophores for Mn2+ to Mitigate Lung Metastasis by Targeting Disseminated Tumor Cell | |
| Abbas et al. | Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas | |
| FR3056108A1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| TWI694838B (zh) | 用於疏水性藥物傳送的新穎以聚合物爲基礎的增溶物 | |
| EP4288053A1 (en) | Small molecule inhibitors of cd38 as immunosuppressants | |
| Wang et al. | Rapamycin and hyperoside-Co-loaded macrophage delivery system enhanced pulmonary fibrosis therapy by autophagy upregulation and epithelial-to-mesenchymal transition inhibition | |
| Watts et al. | Recent developments in drug delivery to prolong allograft survival in lung transplant patients |